TherapeuticsMD (NASDAQ:TXMD) Posts Quarterly Earnings Results

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings data on Wednesday. The company reported $0.01 EPS for the quarter, FiscalAI reports. TherapeuticsMD had a negative return on equity of 2.01% and a negative net margin of 17.94%.The firm had revenue of $0.78 million for the quarter.

TherapeuticsMD Price Performance

TXMD traded up $0.32 on Friday, reaching $1.94. 170,201 shares of the company’s stock were exchanged, compared to its average volume of 230,520. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.44. The stock’s fifty day moving average price is $1.16 and its 200-day moving average price is $1.20. The stock has a market cap of $22.45 million, a PE ratio of -32.25 and a beta of 0.53.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TherapeuticsMD in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, TherapeuticsMD presently has a consensus rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.